TransMedics Group (NASDAQ:TMDX) Stock Price Up 4.7%

TransMedics Group, Inc. (NASDAQ:TMDXGet Free Report)’s share price shot up 4.7% during mid-day trading on Wednesday . The stock traded as high as $76.02 and last traded at $76.00. 59,467 shares were traded during trading, a decline of 90% from the average session volume of 623,417 shares. The stock had previously closed at $72.62.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. JPMorgan Chase & Co. upped their price objective on shares of TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. Morgan Stanley upped their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. Oppenheimer raised their price objective on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 27th. Finally, Piper Sandler began coverage on TransMedics Group in a report on Thursday, March 28th. They set an “overweight” rating and a $95.00 price objective for the company. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $102.00.

Check Out Our Latest Stock Analysis on TransMedics Group

TransMedics Group Stock Up 3.4 %

The firm’s 50 day simple moving average is $82.61 and its two-hundred day simple moving average is $70.50. The firm has a market cap of $2.46 billion, a price-to-earnings ratio of -102.38 and a beta of 1.99. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69.

TransMedics Group (NASDAQ:TMDXGet Free Report) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. The business had revenue of $81.20 million during the quarter, compared to analysts’ expectations of $68.49 million. During the same period in the previous year, the company posted ($0.21) earnings per share. The firm’s revenue for the quarter was up 158.6% compared to the same quarter last year. On average, equities analysts forecast that TransMedics Group, Inc. will post -0.14 EPS for the current year.

Insider Buying and Selling

In other news, CFO Stephen Gordon sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $85.45, for a total transaction of $1,281,750.00. Following the completion of the sale, the chief financial officer now owns 13,075 shares of the company’s stock, valued at approximately $1,117,258.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other TransMedics Group news, Director Edward M. Basile sold 7,157 shares of TransMedics Group stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $86.38, for a total value of $618,221.66. Following the transaction, the director now owns 8,350 shares in the company, valued at $721,273. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Stephen Gordon sold 15,000 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $85.45, for a total transaction of $1,281,750.00. Following the completion of the transaction, the chief financial officer now directly owns 13,075 shares of the company’s stock, valued at approximately $1,117,258.75. The disclosure for this sale can be found here. Insiders sold 92,949 shares of company stock valued at $7,664,819 over the last quarter. 6.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors have recently added to or reduced their stakes in TMDX. American Century Companies Inc. boosted its stake in shares of TransMedics Group by 271.2% during the third quarter. American Century Companies Inc. now owns 486,956 shares of the company’s stock valued at $26,661,000 after purchasing an additional 355,755 shares in the last quarter. Eagle Health Investments LP grew its holdings in TransMedics Group by 78.5% during the 3rd quarter. Eagle Health Investments LP now owns 414,205 shares of the company’s stock worth $22,678,000 after acquiring an additional 182,173 shares during the last quarter. Qube Research & Technologies Ltd increased its position in TransMedics Group by 31.2% in the 3rd quarter. Qube Research & Technologies Ltd now owns 84,450 shares of the company’s stock valued at $4,624,000 after acquiring an additional 20,081 shares during the period. Sei Investments Co. raised its stake in shares of TransMedics Group by 17.8% during the third quarter. Sei Investments Co. now owns 386,082 shares of the company’s stock valued at $21,139,000 after acquiring an additional 58,269 shares during the last quarter. Finally, Blair William & Co. IL acquired a new position in shares of TransMedics Group during the third quarter worth $358,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

(Get Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Recommended Stories

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.